Winona Menopause Telehealth: An Independent Review of the Company, Costs, and Clinical Model

What Is Winona and How Does the Business Model Work?

Winona is a direct-to-consumer telehealth company focused exclusively on menopause hormone therapy for women. The model is straightforward: you complete an online intake questionnaire, a licensed physician reviews your history, and if appropriate, a prescription is sent to a compounding or retail pharmacy and shipped to your door. There are no in-person appointments. No insurance is billed.

That cash-pay structure is deliberate. Insurance reimbursement for telehealth menopause care remains inconsistent across payers, and Winona prices its subscription to make the total cost predictable at around $99 per month, which bundles provider access and, in many cases, medication. For women who have spent years paying $40 copays for a five-minute in-office conversation, the appeal is obvious.

The company positions itself within the broader direct-to-patient hormone therapy market that has grown substantially since the COVID-19 pandemic normalized telehealth prescribing. Competitors in this space include Alloy Women's Health, Midi Health, Gennev (now part of Unified Women's Healthcare), and Evernow. Each platform makes slightly different trade-offs between physician access, formulary breadth, and price.

What Winona Actually Prescribes

Winona's formulary includes both FDA-approved hormone therapy products and custom-compounded bioidentical hormones. The most commonly prescribed agents include:

• Estradiol (transdermal patches, creams, or oral tablets)
• Progesterone (oral micronized progesterone, often brand-name Prometrium or compounded equivalents)
• Testosterone (compounded topical cream, used off-label for libido and energy)
• DHEA (compounded vaginal suppositories for genitourinary syndrome of menopause)
• Combination estrogen-progesterone creams (compounded)

The company leans toward compounded preparations more than some competitors do. That distinction matters clinically, and it is addressed in detail below.

The Intake and Prescribing Process

After the online questionnaire, a physician reviews the submission asynchronously. Most women receive a response within 24 hours. If a provider has follow-up questions, that exchange happens via secure messaging. There is no mandatory synchronous video visit, which is convenient but also means a provider never sees you in real time before prescribing.

Women with more complex histories (prior breast cancer, unexplained uterine bleeding, active cardiovascular disease) should be aware that asynchronous intake has limits. A complex case genuinely benefits from a real-time conversation with a menopause specialist.

The Clinical Case for Menopause HRT: What the Evidence Actually Says

Before evaluating any platform, it helps to anchor to the current evidence on HRT itself.

The Menopause Society 2022 Position Statement states that hormone therapy is the most effective treatment for vasomotor symptoms and is appropriate for healthy women under 60 or within 10 years of menopause onset, absent contraindications. That guidance reversed decades of overcaution following the 2002 Women's Health Initiative (WHI) primary publication.

The WHI findings themselves have been reanalyzed extensively. Manson et al. (2013) in JAMA showed that for women aged 50 to 59 at randomization, conjugated equine estrogen alone was associated with a significantly lower risk of all-cause mortality, myocardial infarction, and breast cancer compared with placebo. The absolute risks look very different from the relative risks that dominated 2002 headlines.

The ACOG Practice Bulletin on Menopausal Hormone Therapy (updated 2022) similarly notes that for symptomatic women under 60 without contraindications, the benefits of systemic HRT generally outweigh risks.

Approximately 51.4% of US women will spend one-third or more of their lives in postmenopause, yet surveys consistently show most are undertreated. That treatment gap is the genuine market need that Winona and its competitors are addressing.

Vasomotor Symptoms: The Core Indication

Hot flashes and night sweats affect up to 80% of women during the menopausal transition. Systemic estradiol is the most effective pharmacological option, with response rates in controlled trials exceeding 75% for moderate-to-severe vasomotor symptoms.

Genitourinary Syndrome of Menopause (GSM)

GSM (vaginal dryness, dyspareunia, urinary urgency) affects an estimated 27 to 84% of postmenopausal women depending on how it is assessed. Low-dose vaginal estrogen and vaginal DHEA (prasterone) are first-line treatments. Winona offers both via prescription.

Bone Health

Estrogen loss after menopause accelerates bone mineral density decline. The North American Menopause Society notes that HRT is FDA-approved for prevention of postmenopausal osteoporosis and may be preferred in women under 60 who also have menopausal symptoms.

Bioidentical vs. FDA-Approved: The Distinction That Winona's Marketing Glosses Over

This is the section most Winona marketing will not walk you through clearly.

"Bioidentical" means the hormone molecule is chemically identical to what your ovaries produced. FDA-approved products like Estrace (estradiol), Prometrium (micronized progesterone), and Divigel (estradiol gel) are also bioidentical by that definition. They have been through rigorous clinical trials, carry standardized dosing, and are subject to FDA manufacturing oversight.

Compounded bioidentical hormone therapy (cBHT) from a 503A compounding pharmacy, which is the kind Winona frequently prescribes, has not been evaluated in large randomized controlled trials for safety and efficacy. The FDA does not verify potency, purity, or sterility of compounded preparations to the same standard. The Endocrine Society's 2016 Scientific Statement concluded there is "no evidence supporting superiority of compounded hormone therapy over conventional hormone therapy."

A simple framework for deciding what matters to you:

| Factor | FDA-Approved HRT | Compounded BHT (Winona's common approach) | |---|---|---| | Large RCT safety data | Yes (WHI, ELITE, KEEPS trials) | No | | Custom dose/formulation | Limited | Yes | | Manufacturing oversight | FDA-regulated | State pharmacy board only | | Insurance coverage | Sometimes | Rarely | | Evidence for equivalence | Established | Extrapolated |

Winona does prescribe FDA-approved products as well. If you have a preference, you can request them. But the intake process does not make the distinction transparent to most users.

Life-Stage Considerations: Who Benefits Most and When

Perimenopause (typically ages 45 to 55)

Perimenopause can begin 8 to 10 years before the final menstrual period. Hormonal fluctuation in this stage is erratic, which makes symptom management more complex than in established postmenopause. Estrogen levels may actually be elevated on some days and low on others.

A telehealth asynchronous intake that captures a single snapshot of your symptoms may miss this variability. Women in early perimenopause with irregular cycles benefit most from a provider who can interpret hormone levels alongside cycle history, not just a questionnaire. If your cycles are still irregular, confirm with your Winona provider whether baseline labs (FSH, estradiol, thyroid) will be ordered before prescribing.

Postmenopause (12 or more months after final period)

This is where Winona's model fits most cleanly. Symptoms are more stable, the diagnosis is clinical, and a straightforward HRT protocol can be started with reasonable confidence. The 10-year window from menopause onset, emphasized by The Menopause Society 2022 Position Statement, is the period of maximum benefit and minimum risk for most healthy women.

Surgical Menopause (any age)

Women who have had a bilateral oophorectomy before natural menopause face an abrupt, severe drop in estrogen with no transition period. They often require higher estrogen doses than women who experience natural menopause. Winona can prescribe in this scenario but the complexity argues for at least one synchronous visit with the provider.

Women with PCOS

Women with polycystic ovary syndrome who are approaching perimenopause have distinct metabolic considerations. They may have had years of estrogen dominance relative to progesterone, and the picture changes at menopause. Research published in Menopause (2021) notes that women with PCOS may experience different timing of menopause and potentially different cardiovascular risk profiles. Winona's intake questionnaire does not explicitly stratify PCOS patients, which is a gap.

Pregnancy, Lactation, and Contraception: What You Must Know Before Starting HRT

HRT is contraindicated in confirmed pregnancy. This is not ambiguous.

Estrogen and progesterone preparations used for menopause management have not been shown to be safe in pregnancy and should not be taken if you are pregnant or suspect you may be pregnant.

Perimenopause and Pregnancy Risk

This is genuinely underappreciated. A woman in perimenopause can still ovulate and conceive. ACOG advises using reliable contraception until 12 full months have passed since the last menstrual period (the clinical definition of menopause). Starting HRT before that point does not eliminate pregnancy risk and does not substitute for contraception.

If you are perimenopausal and still having any menstrual cycles, you need contraception alongside any hormone therapy. Low-dose combined oral contraceptives or a progestin-containing IUD can serve dual purposes: contraception and symptom management. Discuss this explicitly with your Winona provider before your protocol is finalized.

Lactation

HRT in the context of postpartum or breastfeeding is a separate clinical scenario from menopausal HRT and is outside Winona's standard scope. Systemic estrogen can reduce milk supply. Postpartum women experiencing hot flashes (a real phenomenon driven by postpartum estrogen withdrawal) should speak with an OB-GYN or lactation-specialist provider rather than a menopause telehealth platform.

Contraindications to HRT (Screen Yourself Before Signing Up)

You should not start HRT, including through Winona, if you have:

• Current or recent (within 5 years) estrogen receptor-positive breast cancer
• Undiagnosed abnormal uterine bleeding
• Active or recent venous thromboembolism (DVT or pulmonary embolism)
• Active liver disease
• Untreated or unstable cardiovascular disease
• Confirmed pregnancy

Winona's intake questionnaire asks about most of these. Be accurate and complete in your responses. The asynchronous model means there is no safety net of a clinician observing inconsistencies in real time.

How Much Does Winona Cost?

Winona's published pricing sits at approximately $99 per month for a subscription that includes provider consultations and many medications. Some compounded formulations carry additional pharmacy fees that can bring the real monthly total to $120 to $180 depending on the protocol.

For comparison:

• Alloy Women's Health: $25 to $85 per month depending on treatment
• Midi Health: accepts insurance for provider visits; medication cost varies
• Evernow: $99 per month subscription model similar to Winona
• Gennev: integrated with Unified Women's Healthcare; pricing varies by service
• Out-of-pocket at a gynecologist: provider visit $150 to $350, plus pharmacy costs for the medication separately

Women with insurance that covers HRT medications may find a traditional in-network provider cheaper than any telehealth cash-pay platform once prescription coverage is factored in. Call your insurance before assuming telehealth is the budget option.

Is Winona Legit? Evaluating the Platform Against Clinical Standards

Winona employs licensed physicians (primarily gynecologists and internists with menopause training) who prescribe within the laws of each state. The platform is not a hormone mill pushing prescriptions without clinical review. Several specific concerns are worth naming.

What Winona Does Well

• Provider access for women who live in underserved areas with no local menopause specialist
• Predictable monthly pricing with medication included
• Attention to symptoms that are frequently dismissed in brief in-person visits
• A formulary that covers both systemic and local (vaginal) hormone therapy

Where Winona Falls Short

• Compounded formulations are offered without consistently foregrounding the evidence limitations relative to FDA-approved products
• Asynchronous-only intake for most patients limits clinical nuance for complex cases
• No built-in pathway for mammography reminder, bone density screening referral, or cardiovascular risk stratification, all of which ACOG recommends alongside HRT management
• The online questionnaire does not appear to apply a validated symptom scoring tool such as the Menopause Rating Scale or the Greene Climacteric Scale, making objective follow-up tracking difficult

What Real Women Report

User reviews on independent platforms (Trustpilot, Reddit r/menopause, Google) are largely positive regarding symptom relief and provider responsiveness. The most common complaints center on shipping delays, unclear communication about compounded vs. FDA-approved options, and difficulty reaching a live provider for urgent questions.

A WomanRx editorial board member, Elena Vasquez MD (OB-GYN), reviewed Winona's published prescribing framework and noted: "The platform fills a real access gap. My concern is that the compounded-first approach normalizes preparations that carry less regulatory oversight, without consistently giving patients the information they need to make that trade-off consciously. Women deserve that conversation upfront, not buried in fine print."

Winona vs. Alternatives: A Comparative Look

The menopause telehealth market is not uniform. Here is how Winona sits relative to key competitors on the factors that matter most clinically.

| Platform | Synchronous Visits | Insurance Accepted | FDA-Approved Products | Compounded BHT | Lab Ordering | |---|---|---|---|---|---| | Winona | Optional (some plans) | No | Yes | Yes (primary) | Yes (some states) | | Alloy | Yes (video) | No | Yes | Limited | Yes | | Midi Health | Yes (video) | Yes (some) | Yes | Limited | Yes | | Evernow | Async + messaging | No | Yes | Yes | Yes | | Gennev | Yes (video) | Varies | Yes | Limited | Yes |

Women who want a synchronous video visit as the default, or who need insurance billing, may find Midi Health or Gennev a better fit. Women who prioritize price and convenience and whose menopause history is straightforward will find Winona adequate.

Who This Is Right For and Who Should Look Elsewhere

Winona may suit you if:

• You are in established postmenopause (12 or more months since your last period) with moderate-to-severe vasomotor symptoms
• You have no significant contraindications to HRT and a clear, uncomplicated medical history
• You have already had a recent mammogram, pelvic exam, and basic bloodwork and simply need ongoing hormone management
• You are comfortable with asynchronous provider communication
• Local menopause-trained providers are unavailable or unaffordable

Winona is likely not the best fit if:

• You are still in early perimenopause with irregular cycles and need nuanced cycle-aware management
• You have a history of breast cancer, thromboembolic disease, or undiagnosed abnormal uterine bleeding
• You have PCOS, thyroid disease, or adrenal conditions that require coordinated management alongside HRT
• You need or want a synchronous relationship with a named clinician who can review imaging, labs, and your full chart in real time
• You are postpartum or breastfeeding

The Evidence Gap Women Should Know About

Women have been systematically underrepresented in hormone therapy research for decades. The WHI enrolled women with a mean age of 63, meaning much of the foundational safety data applies to women a decade or more past menopause rather than to the perimenopausal or newly postmenopausal woman most likely to use Winona.

The KEEPS trial (Kronos Early Estrogen Prevention Study) specifically enrolled women within 3 years of menopause and found oral conjugated equine estrogen and transdermal estradiol did not significantly affect carotid artery intima-media thickness progression over 4 years, with some favorable effects on quality of life and mood. This is more directly relevant to the Winona target user than the original WHI data.

Compounded bioidentical preparations have even thinner evidence. No large RCT has compared compounded estradiol plus progesterone cream to FDA-approved transdermal estradiol plus oral micronized progesterone for cardiovascular, breast, or bone endpoints. Extrapolation is being made. Women using Winona should know they are in that extrapolated zone when using compounded products, not the zone directly studied in KEEPS or WHI.